Aquestive Therapeutics (AQST) Liabilities and Shareholders Equity (2017 - 2025)
Historic Liabilities and Shareholders Equity for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $163.6 million.
- Aquestive Therapeutics' Liabilities and Shareholders Equity rose 4874.68% to $163.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $460.9 million, marking a year-over-year increase of 1119.68%. This contributed to the annual value of $101.4 million for FY2024, which is 7664.15% up from last year.
- Per Aquestive Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $163.6 million for Q3 2025, which was up 4874.68% from $93.7 million recorded in Q2 2025.
- Aquestive Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $163.6 million during Q3 2025, with a 5-year trough of $51.8 million in Q3 2022.
- Moreover, its 5-year median value for Liabilities and Shareholders Equity was $62.0 million (2021), whereas its average is $80.6 million.
- In the last 5 years, Aquestive Therapeutics' Liabilities and Shareholders Equity skyrocketed by 11134.54% in 2024 and then crashed by 2106.88% in 2025.
- Aquestive Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $62.0 million in 2021, then decreased by 7.94% to $57.1 million in 2022, then increased by 0.61% to $57.4 million in 2023, then surged by 76.64% to $101.4 million in 2024, then skyrocketed by 61.26% to $163.6 million in 2025.
- Its last three reported values are $163.6 million in Q3 2025, $93.7 million for Q2 2025, and $102.2 million during Q1 2025.